Executive Director, Asset Strategy Lead and Clinical Lead, Early Development

Syndax Pharmaceuticals is looking for an

Executive Director, Asset Strategy Lead and Clinical Lead, Early Development

At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies.

The Role

The Asset Strategy Lead (ASL), Early Development provides leadership to a cross-functional strategic asset team and leads the development and execution of the asset strategy. Further, the ASL champions the product/brand at all levels of Syndax and is responsible for managing the alignment on communication on all Asset Strategy Team (AST) matters, as appropriate.

We are seeking an Executive Director, Asset StrategyLead for our recently announced Next Generation Menin Program. During the early stages of development, the role will also assume the responsibility of clinical lead for the program. The ideal candidate will bring a demonstrated record of strategic leadership and operational excellence in global oncology product development, with experience leading early-stage programs through pre-IND activities through pivotal studies, and potentially regulatory approval and commercialization.

This role will be a key member of the Syndax senior leadership team, influencing portfolio strategy and execution. The ideal candidate will lead the asset with a long-term enterprise view, integrating scientific, clinical, regulatory, commercial, and financial perspectives to optimize asset value.

Key Responsibilities

• Own end-to-end leadership of the asset strategy, from early development through regulatory filings, approval, launch, and lifecycle management.
• Drive the strategic direction of the program in alignment with corporate objectives, balancing scientific innovation, clinical value, and commercial opportunity.
• Identifies potential issues and leads